These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 17235522)
1. Comment on: Distiller LA, Joffe BI (2006) From the coalface: does glargine insulin improve hypoglycaemic episodes, glycaemic control or affect body mass in type 1 diabetic subjects who are attending a 'routine' diabetes clinic? Diabetologia 49:2793-2794. Bell DS Diabetologia; 2007 Mar; 50(3):695. PubMed ID: 17235522 [No Abstract] [Full Text] [Related]
2. From the coalface: does glargine insulin improve hypoglycaemic episodes, glycaemic control or affect body mass in type 1 diabetic subjects who are attending a 'routine' diabetes clinic? Distiller LA; Joffe BI Diabetologia; 2006 Nov; 49(11):2793-4. PubMed ID: 17047914 [No Abstract] [Full Text] [Related]
3. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes. Schober E; Schoenle E; Van Dyk J; Wernicke-Panten K; Diabetes Care; 2001 Nov; 24(11):2005-6. PubMed ID: 11679478 [No Abstract] [Full Text] [Related]
4. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Garg SK; Gottlieb PA; Hisatomi ME; D'Souza A; Walker AJ; Izuora KE; Chase HP Diabetes Res Clin Pract; 2004 Oct; 66(1):49-56. PubMed ID: 15364161 [TBL] [Abstract][Full Text] [Related]
5. Insulin glargine: a new basal insulin analogue. Younis N; Soran H; Bowen-Jones D QJM; 2002 Nov; 95(11):757-61. PubMed ID: 12391389 [No Abstract] [Full Text] [Related]
6. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients. Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403 [TBL] [Abstract][Full Text] [Related]
7. Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial. Heise T; Bain SC; Bracken RM; Zijlstra E; Nosek L; Stender-Petersen K; Rabøl R; Rowe E; Haahr HL Diabetes Obes Metab; 2016 Feb; 18(2):196-9. PubMed ID: 26450456 [TBL] [Abstract][Full Text] [Related]
8. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes. Marre M; Pinget M; Gin H; Thivolet C; Hanaire H; Robert JJ; Fontaine P Diabetes Metab; 2009 Dec; 35(6):469-75. PubMed ID: 19914118 [TBL] [Abstract][Full Text] [Related]
9. Optimizing glycemic control with insulin glargine. Williams JB Diabetes Technol Ther; 2003; 5(3):471-3. PubMed ID: 12828834 [No Abstract] [Full Text] [Related]
10. Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes: the role of insulin analogs. Rossetti P; Porcellati F; Bolli GB; Fanelli CG Diabetes Care; 2008 Feb; 31 Suppl 2():S113-20. PubMed ID: 18227470 [No Abstract] [Full Text] [Related]
11. Feasibility of continuous subcutaneous insulin infusion and daily supplemental insulin glargine injection in children with type 1 diabetes. Alemzadeh R; Parton EA; Holzum MK Diabetes Technol Ther; 2009 Aug; 11(8):481-6. PubMed ID: 19698060 [TBL] [Abstract][Full Text] [Related]
12. Initiation of insulin glargine in children and adolescents with type 1 diabetes. Tan CY; Wilson DM; Buckingham B Pediatr Diabetes; 2004 Jun; 5(2):80-6. PubMed ID: 15189493 [TBL] [Abstract][Full Text] [Related]
13. Reconsideration of severe hypoglycemic events in the treat-to-target trial. Dailey G; Strange P; Riddle M Diabetes Technol Ther; 2009 Aug; 11(8):477-9. PubMed ID: 19698059 [TBL] [Abstract][Full Text] [Related]
14. Use of insulin glargine during pregnancy in a type 1 diabetic woman. Devlin JT; Hothersall L; Wilkis JL Diabetes Care; 2002 Jun; 25(6):1095-6. PubMed ID: 12032121 [No Abstract] [Full Text] [Related]
15. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study. Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471 [TBL] [Abstract][Full Text] [Related]
16. [Tramadol-induced hypoglycemia in a diabetic patient]. Jonville-Bera A-; Marie A; Magba D; Gedon E; Autret-Leca E Therapie; 2010; 65(5):499-500. PubMed ID: 21416746 [No Abstract] [Full Text] [Related]
17. Insulin glargine: a long-acting insulin for diabetes mellitus. Garces K Issues Emerg Health Technol; 2003 Nov; (52):1-4. PubMed ID: 14626260 [TBL] [Abstract][Full Text] [Related]
18. Reducing mistakes in patient administration of glargine and lispro. Schutta MH Diabetes Care; 2002 Jun; 25(6):1098-9. PubMed ID: 12032124 [No Abstract] [Full Text] [Related]
19. Use of insulin glargine during embryogenesis in a pregnant woman with Type 1 diabetes. Holstein A; Plaschke A; Egberts EH Diabet Med; 2003 Sep; 20(9):779-80. PubMed ID: 12925063 [No Abstract] [Full Text] [Related]
20. Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes. Rosenstock J; Blevins TC; Bergenstal RM; Morrow LA; Qu Y; Jacober SJ J Diabetes; 2016 Jan; 8(1):166-9. PubMed ID: 26278063 [No Abstract] [Full Text] [Related] [Next] [New Search]